In 47 out of 100 tested patients with highest methylation level (> 14%) and absent or low BRCA1 expression in tumor tissue (< 10% cells with immunoreactivity), we searched for germline alterations in the BRCA1 promoter region. This evidence concerns the gene BRCA1 and neoplasm.